IMNM Stock Risk & Deep Value Analysis
Immunome Inc
DVR Score
out of 10
What You Need to Know About IMNM Stock
We analyzed Immunome Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IMNM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IMNM Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a clinical trial failure or a negative regulatory outcome for varegacestat (AL102), which is the company's most advanced and critical asset. Such an event would severely impact the investment thesis, leading to significant stock devaluation and potentially necessitating further dilutive financing rounds.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Reliance on a single lead asset (varegacestat) for near-term revenue generation.
- ⚠
Typical high cash burn rate of a clinical-stage biotech without a clear timeline to profitability.
- ⚠
Limited detailed financial data available in the provided real-time brief, though public filings are available.
Upcoming Risk Events
- 📅
Negative or unclear clinical trial data for lead assets
- 📅
Delayed or unfavorable regulatory decisions by the FDA
- 📅
Significant future capital raises leading to substantial shareholder dilution
When to Reconsider
- 🚪
Negative Phase 3 data results for varegacestat or a complete response letter (CRL) from the FDA.
- 🚪
Prolonged stock price weakness below $20.00 without clear catalysts or news.
- 🚪
Significant, unexpected insider selling by multiple executives, especially if not pre-planned.
Unlock IMNM Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Immunome is a high-risk, high-reward investment positioned for 10x growth within 3-5 years, primarily driven by its lead oncology asset, varegacestat (AL102), for desmoid tumors. Its potential superiority over existing treatments, coupled with a strategic acquisition model and a proprietary discovery platform, establishes a strong foundation for future market leadership and accelerated revenue generation in a high-value oncology niche.
Is IMNM Stock Undervalued?
Unlock the full AI analysis for IMNM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IMNM Price Targets & Strategy
12-Month Target
$35.00
Bull Case
$42.00
Bear Case
$15.00
Valuation Basis
Valuation based on anticipated market penetration and peak sales of varegacestat, assuming successful regulatory approval and differentiation against existing therapies.
Entry Strategy
Consider dollar-cost averaging in the $22.00-$25.00 range, especially on dips towards the CEO's recent purchase price of $19.67, which may act as a support zone.
Exit Strategy
Take partial profits at $35.00, re-evaluate at $40.00-$42.00. Implement a stop-loss order if the stock breaks below $19.00, indicating a loss of key support and insider conviction level.
Portfolio Allocation
7% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is IMNM Financially Healthy?
Valuation
P/E Ratio
-8.27
Price/Book
3.90
Profitability
Operating Margin
-1784.14%
Net Margin
-1687.08%
Return on Equity
-57.61%
Revenue Growth
-23.23%
EPS
$-2.41
Balance Sheet
Current Ratio
14.69
Quick Ratio
14.53
Cash Flow
EBITDA
-$188.42M
Other
Beta (Volatility)
2.18
Does IMNM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Immunome's moat is driven primarily by its intellectual property for novel therapeutic antibodies. The durability relies on successful patent defense and continued innovation from its discovery platform. If varegacestat demonstrates clear superiority and achieves market leadership, this clinical differentiation will strengthen the moat, but it remains susceptible to competition from new treatments or biosimilars post-patent expiry.
Moat Erosion Risks
- •Clinical trial failures or safety concerns that undermine product differentiation.
- •Development of more effective or safer competing therapies by rivals.
- •Patent challenges or expiry, leading to generic/biosimilar competition.
IMNM Competitive Moat Analysis
Sign up to see competitive advantages
IMNM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-Positive (based on analyst and insider activity, no specific social media data available)
Institutional Sentiment
Positive (Moderate Buy consensus from analysts, H.C. Wainwright initiated Buy, Lake Street Capital raised target)
Insider Activity (Form 4)
CEO Clay B. Siegall bought 25,450 shares on March 27, 2026, at $19.67 ($500,601). CSO Jack Higgins sold 9,438 shares on April 2, 2026, at $21.64 ($204,238) under a 10b5-1 plan. CFO exercised options and sold 65,000 shares around April 3, 2026, contributing to total insider sales of approximately 139,438 shares (~$2.96M) over 90 days. Net insider activity shows CEO conviction offset by other planned sales.
Options Flow
Normal options activity (no specific data available in the brief)
Earnings Intelligence
Next Earnings
2026-05-11 (Q1 2026 estimated announcement)
Surprise Probability
Medium
Historical Earnings Pattern
Biotech stocks like Immunome typically exhibit high volatility around clinical trial data releases and regulatory milestones, which often overshadow quarterly financial results.
Key Metrics to Watch
Competitive Position
Top Competitor
SWTX (SpringWorks Therapeutics)
Market Share Trend
Positioned to gain significant market share in the desmoid tumor segment upon successful approval and commercialization of varegacestat.
Valuation vs Peers
Likely trading at a premium to some clinical-stage biotechs due to its late-stage asset and 'potentially superior' claim, but still below commercial-stage peers.
Competitive Advantages
- •Potentially superior gamma-secretase inhibitor (varegacestat) for desmoid tumors.
- •Proprietary human antibody discovery platform providing a pipeline generation engine.
- •Accelerated path to market through strategic asset acquisition.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IMNM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (estimated May 11, 2026)
- •Continued positive oncology data updates for lead assets (varegacestat, AL101)
Medium-Term (6-18 months)
- •Potential NDA filing for varegacestat (AL102) for Desmoid Tumors (expected within 6-18 months)
- •Additional clinical trial data readouts for other pipeline candidates (e.g., AL101 Phase 3 data)
Long-Term (18+ months)
- •Commercialization and market penetration of varegacestat in desmoid tumors
- •Expansion of proprietary antibody discovery platform into new therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IMNM?
- ✓
Positive Phase 3 clinical trial results for AL101 or other pipeline assets.
- ✓
FDA acceptance of NDA for varegacestat and subsequent approval.
- ✓
Significant increase in institutional ownership and further analyst upgrades.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Immunome Inc Makes Money
Immunome Inc. is a clinical-stage biotechnology company that discovers and develops novel antibody therapeutics for cancer and infectious diseases. It utilizes a unique proprietary platform to identify naturally occurring, potent antibodies from patients who have successfully fought off diseases, leveraging the human immune system's insights. While its long-term strategy includes its own antibody pipeline, its near-term growth and revenue potential are significantly bolstered by strategically acquired late-stage oncology assets, such as varegacestat for desmoid tumors. The company aims to generate revenue through the development, regulatory approval, and eventual commercialization of these therapeutic antibodies for patient use.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Immunome Inc (IMNM)?
As of April 18, 2026, Immunome Inc has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Immunome Inc?
Immunome Inc's market capitalization is approximately $2.6B..
What is the risk level for IMNM stock?
Our analysis rates Immunome Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IMNM?
Immunome Inc currently has a price-to-earnings (P/E) ratio of -8.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Immunome Inc's revenue growing?
Immunome Inc has reported revenue growth of -23.2%. Revenue has been declining, which warrants closer examination.
Is IMNM stock profitable?
Immunome Inc has a profit margin of -1687.1%. The company is currently unprofitable.
How often is the IMNM DVR analysis updated?
Our AI-powered analysis of Immunome Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 18, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IMNM (Immunome Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.